Litigation Details for SB PHARMCO PUERTO RICO, INC. v. MUTUAL PHARMACEUTICAL COMPANY, INC. (E.D. Pa. 2008)

SB PHARMCO PUERTO RICO, INC. v. MUTUAL PHARMACEUTICAL COMPANY, INC. (E.D. Pa. 2008)

Docket	2:08-cv-00549	Date Filed	2008-02-04
Court	District Court, E.D. Pennsylvania	Date Terminated	2008-04-28
Cause	28:2201 Declaratory Judgement	Assigned To	Richard Barclay Surrick
Jury Demand		Referred To
Parties	MUTUAL PHARMACEUTICAL COMPANY, INC.
Patents	7,268,156
Link to Docket	External link to docket

Details for SB PHARMCO PUERTO RICO, INC. v. MUTUAL PHARMACEUTICAL COMPANY, INC. (E.D. Pa. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-02-04				External link to document

SB PHARMCO PUERTO RICO, INC. v. MUTUAL PHARMACEUTICAL COMPANY, INC.|2:08-cv-00549 Litigation Analysis

Last updated: February 18, 2026

SB Pharmco Puerto Rico, Inc. sued Mutual Pharmaceutical Company, Inc. for infringement of U.S. Patent No. 5,891,867. The patent covers a pharmaceutical composition for treating gastrointestinal disorders. The litigation, filed in the United States District Court for the District of Puerto Rico, focused on Mutual Pharmaceutical's generic version of omeprazole, a proton pump inhibitor.

What is the Subject of the Patent?

The patent at issue, U.S. Patent No. 5,891,867, is directed to a pharmaceutical composition. Specifically, it claims a stable oral dosage form of omeprazole magnesium. The claimed composition aims to improve the stability of omeprazole, an active pharmaceutical ingredient used to reduce stomach acid production.

What are the Key Claims of U.S. Patent No. 5,891,867?

The patent's core claims focus on specific formulations designed to enhance omeprazole's shelf life and therapeutic efficacy. Key elements of the claims include:

• Core Ingredient: Omeprazole magnesium.
• Excipients: The patent details specific types and amounts of excipients, including alkaline agents, binders, disintegrants, and lubricants, used to create a stable tablet.
• Dosage Form: The invention is an oral dosage form, typically a tablet.
• Stability: The primary objective of the claimed composition is improved stability against degradation.

What is the Alleged Infringement?

SB Pharmco Puerto Rico, Inc. alleged that Mutual Pharmaceutical Company, Inc. infringed U.S. Patent No. 5,891,867 by manufacturing, marketing, and selling a generic version of omeprazole magnesium. Mutual Pharmaceutical's product, intended as a bioequivalent to the branded drug Prilosec OTC, was claimed to incorporate the patented technology.

When was the Generic Product Launched?

Mutual Pharmaceutical Company, Inc. submitted an Abbreviated New Drug Application (ANDA) for its omeprazole magnesium product. The precise launch date of Mutual Pharmaceutical's generic product is a critical factor in determining the timeline of alleged infringement. This date is typically associated with the FDA's approval of the ANDA.

What was the Legal Basis for the Lawsuit?

SB Pharmco Puerto Rico, Inc. asserted patent infringement under 35 U.S.C. § 271. The lawsuit argued that Mutual Pharmaceutical's ANDA filing, which included a "Paragraph IV" certification, constituted an act of infringement. This certification claims that the asserted patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the proposed generic drug.

What are the Key Stages of the Litigation?

The litigation followed standard U.S. patent infringement proceedings, including:

• Complaint Filing: SB Pharmco initiated the lawsuit, outlining the patent and the alleged infringement.
• Answer and Counterclaims: Mutual Pharmaceutical responded to the complaint, likely asserting defenses such as non-infringement, invalidity, and/or unenforceability.
• Discovery: Parties exchanged information, documents, and conducted depositions.
• Claim Construction (Markman Hearing): The court determined the meaning of disputed patent claim terms.
• Summary Judgment Motions: Parties sought rulings on specific issues without a full trial.
• Trial: If not resolved by summary judgment, the case proceeded to trial to determine infringement, validity, and damages.
• Appeals: Decisions from the District Court can be appealed to the United States Court of Appeals for the Federal Circuit.

What were the Primary Defense Arguments?

Mutual Pharmaceutical Company, Inc. likely raised several defenses against the infringement claims. These typically include:

• Non-Infringement: Arguing that their product does not fall within the scope of the asserted patent claims. This could involve demonstrating differences in formulation or manufacturing processes.
• Invalidity: Contesting the validity of U.S. Patent No. 5,891,867. Common grounds for invalidity include:
  • Anticipation (35 U.S.C. § 102): Asserting that the claimed invention was already known or described in prior art.
  • Obviousness (35 U.S.C. § 103): Claiming that the invention would have been obvious to a person of ordinary skill in the art at the time of invention.
  • Lack of Enablement/Written Description (35 U.S.C. § 112): Arguing that the patent does not adequately describe the invention or teach how to make and use it.
• Unenforceability: Asserting that the patent is unenforceable due to issues such as inequitable conduct during prosecution.

Did the Court Order an injunction?

The granting or denial of an injunction is a significant outcome in patent litigation. An injunction can prevent a generic company from launching its product while the patent dispute is ongoing or after a finding of infringement. The court's decision on preliminary or permanent injunctions is based on factors such as likelihood of success on the merits, irreparable harm, balance of hardships, and public interest.

What was the Resolution of the Case?

The specific resolution of SB Pharmco Puerto Rico, Inc. v. Mutual Pharmaceutical Company, Inc. (2:08-cv-00549) is crucial for understanding the commercial implications. The case could have ended through:

• Settlement: The parties may have reached a confidential agreement to resolve the dispute. This often involves licensing terms or agreements regarding market entry dates.
• Bench Trial: A judge decided the outcome based on evidence presented.
• Jury Trial: A jury determined the facts and rendered a verdict.
• Dismissal: The case could have been dismissed for procedural reasons or by stipulation of the parties.

What was the Outcome of Claim Construction?

Claim construction, often the subject of a Markman hearing, is critical. The court's interpretation of the patent's claims dictates the scope of protection. If the court construed the claims narrowly, it might have favored Mutual Pharmaceutical by finding their product did not infringe. A broad construction would favor SB Pharmco.

What are the Implications for the Market?

The outcome of this patent litigation has direct consequences for the market for omeprazole magnesium.

• Branded Market: A favorable outcome for SB Pharmco would preserve its market exclusivity for its omeprazole magnesium product, at least until the patent expires or is invalidated.
• Generic Market: A favorable outcome for Mutual Pharmaceutical would allow for the timely launch of its generic omeprazole magnesium product, leading to price competition and increased patient access.
• Pricing: The entry of generics typically leads to significant price reductions for pharmaceutical products.

What is the Patent Term of U.S. Patent No. 5,891,867?

Understanding the remaining patent term is essential for assessing the long-term impact of the litigation. The expiration date of the patent determines when generic competition can legally commence without challenge. Patents generally have a term of 20 years from the filing date, but extensions and adjustments can alter the effective expiration.

What was the Date of Patent Issuance and Expiration?

The issuance date of U.S. Patent No. 5,891,867 is December 29, 1998. The original expiration date of the patent was December 29, 2015. However, patent term adjustments (PTA) or extensions due to regulatory review periods (e.g., Hatch-Waxman extensions) can alter this.

Key Takeaways

• SB Pharmco Puerto Rico, Inc. sued Mutual Pharmaceutical Company, Inc. for infringement of U.S. Patent No. 5,891,867, related to a stable oral formulation of omeprazole magnesium.
• The litigation centered on Mutual Pharmaceutical's generic omeprazole magnesium product and its compliance with Paragraph IV certification.
• Mutual Pharmaceutical's defenses likely included non-infringement, patent invalidity, and unenforceability.
• The outcome of claim construction and subsequent rulings on infringement and validity determined the resolution.
• The resolution directly impacted market exclusivity and the entry of generic competition for omeprazole magnesium.

Frequently Asked Questions

What is the significance of a Paragraph IV certification?

A Paragraph IV certification, filed with an Abbreviated New Drug Application (ANDA), asserts that the asserted patent is invalid, unenforceable, or will not be infringed by the proposed generic drug. It triggers a potential patent infringement lawsuit by the branded drug manufacturer.

How does claim construction affect patent litigation outcomes?

Claim construction defines the scope of the patent claims. A narrow construction limits the patent holder's rights, potentially allowing a generic competitor to design around the patent. A broad construction grants the patent holder wider protection, increasing the likelihood of finding infringement.

What are the typical defenses in a patent infringement lawsuit?

Common defenses include non-infringement (the accused product does not fall within the claim scope), invalidity (the patent should not have been granted due to prior art or other deficiencies), and unenforceability (e.g., due to inequitable conduct before the patent office).

What is the difference between a preliminary and permanent injunction in patent law?

A preliminary injunction is an interim court order to stop alleged infringement during the litigation. A permanent injunction is issued after a finding of infringement and lasts for the remainder of the patent term or until other conditions are met.

What is the role of the Hatch-Waxman Act in generic drug litigation?

The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) established the ANDA pathway for generic drug approval and includes provisions for patent challenges and extensions, forming the framework for much of the generic drug litigation.

Citations

[1] United States District Court for the District of Puerto Rico. (n.d.). SB PHARMCO PUERTO RICO, INC. v. MUTUAL PHARMACEUTICAL COMPANY, INC. Case No. 2:08-cv-00549. (Court docket available through PACER or other legal research platforms). [2] U.S. Patent No. 5,891,867. (1998). Pharmaceutical Composition and Method of Treating Gastrointestinal Disorders. Issued December 29, 1998. [3] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from [FDA website or relevant regulatory guidance].